Wednesday, July 29, 2026
← Back to archivePolicy
Policy•STAT News•Jul 29, 2026
Opinion: Prolonged hospital stays can leave children isolated. It needs to change
background ▾
- •This is an opinion/commentary piece with no clinical trial results, regulatory decisions, or policy announcements—it does not constitute actionable industry news
Policy•Fierce Biotech•Jul 28, 2026
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
background ▾
- •GSK is executing a major cost-restructuring plan to offset the 2028 patent cliff for dolutegravir HIV medicines (Dovato/Tivicay; £1.4B Q2 revenue) and fund advancement of specialty oncology and hepatology assets
- •The Cambridge R&D relocation signals commitment to U.K. life sciences ecosystems and academic partnerships but raises questions about job losses and operational disruption in Stevenage
- •Watch for: formal headcount disclosure in coming months, execution fidelity on the 25-study acceleration program across oncology/respiratory/hepatology, and whether ris-rez and neladalkib achieve clinical/commercial milestones to justify reinvestment
GSKHansoh PharmaceuticalAstraZenecadolutegravirDovatoTivicay
→ Read original articlePolicy•STAT News•Jul 29, 2026
Opinion: The VA could help America win the biotechnology race with China
background ▾
- •The U.S. VA system could be repurposed as critical biotechnology infrastructure to accelerate drug development timelines and clinical trial efficiency in competition with China's biotech investments.
- •HHS has launched Operation Trialblazer to modernize clinical research through adaptive designs, AI integration, and real-world evidence; incorporating the VA could amplify this national strategy.
- •Watch for VA operational partnerships with FDA/NIH, actual integration into Operation Trialblazer framework, and pilot adaptive trial programs leveraging VA's EHR data.
Policy•Endpoints News•Jul 28, 2026
FDA reminds investors about the risks of advisory panels
background ▾
- •FDA briefing documents expressing clinical data concerns can trigger substantial market reactions even before advisory panel convening
Policy•STAT News•Jul 28, 2026
Six key issues we’re watching at Fauci’s hearing
background ▾
- •Republicans are using the hearing strategically to establish grounds for potential perjury charges against Fauci despite his existing pardon, with Health Secretary RFK Jr. and Senator Paul suggesting new criminal prosecution could proceed if testimony provides opportunity.
Market Access
Market Access•Endpoints News•Jul 29, 2026
Leqembi records best quarter since launch as Biogen raises guidance
background ▾
- •Leqembi Q2 sales of $184M represent best-ever quarterly performance, indicating strengthening commercial momentum post-launch
- •Biogen raised full-year guidance based on Leqembi acceleration, suggesting confidence in sustained demand and market expansion
- •Watch for: Q3/Q4 2024 trajectory, insurance coverage expansion, and competitive positioning as other anti-amyloid candidates (donanemab, remternetug) advance
BiogenEisaiLeqembilecanemab
→ Read original articleMarket Access•Fierce Biotech•Jul 28, 2026
Eli Lilly tops new biopharma ranking on launch success, development speed
background ▾
- •Eli Lilly's #1 ranking reflects superior execution across multiple dimensions—not just GLP-1 success—including exceptional phase 1 failure identification, above-average trial success rates, and efficient portfolio management relative to R&D spend
- •Smaller specialized companies (Vertex, Daiichi Sankyo, UCB) are outperforming by narrowing focus on specific disease areas or modalities, achieving superior development timelines and trial outcomes through deep therapeutic expertise
- •Troubling industry signal: pipeline creation down 32% while R&D spending up 45% suggests biopharma is becoming less productive at generating early-stage assets despite increased investment, potentially indicating consolidation pressures and rising development costs
Eli LillyNovo NordiskRoche
→ Read original articleMarket Access•Fierce Biotech•Jul 28, 2026
Guardant Health taps Patrick Dempsey for emotional colorectal cancer awareness video
background ▾
- •Guardant is leveraging celebrity endorsement to drive awareness and adoption of Shield in a crowded blood-test screening market where clinical efficacy still lags traditional methods
- •The campaign addresses a real epidemiological shift: colorectal cancer is now the leading cancer killer in under-50 patients in the U.S., with incidence rising ~3% annually in this age group
Guardant HealthFreenomeAbbottShieldSimpleScreen CRC
→ Read original articleMarket Access•Endpoints News•Jul 28, 2026
Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3
background ▾
- •Oak Hill Bio secures public market access via RA Capital SPAC merger, enabling acceleration of Angelman syndrome pipeline
- •InnoCare's TYK2 inhibitor progresses to Phase 3, advancing the company's position in the competitive TYK2 inhibitor landscape
- •Monitor Oak Hill's post-merger cash runway and InnoCare's Phase 3 efficacy/safety readout timeline for value inflection points
Oak Hill BioRA CapitalInnoCareTYK2 inhibitor
→ Read original articleMarket Access•Endpoints News•Jul 28, 2026
Alnylam's stock is down 30% despite a booming biotech market. Here's why
background ▾
- •Alnylam's 30% stock decline contrasts sharply with biotech sector recovery, signaling company-specific headwinds
- •Market access or commercial execution issues appear to be the primary concern driving valuation multiple compression
Alnylam Pharmaceuticals
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jul 28, 2026
‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drug
background ▾
- •CSB-001 originated from a failed neurotrophic keratitis trial but showed unexpected benefit in LSCD patients, representing a novel disease-indication pivot with therapeutic potential in an unmet medical need affecting 30,000+ U.S. patients under treatment
- •Novo Holdings' significant backing and the $118M Series B capital raise signal institutional confidence, though Phase 3 success is not assured and the addressable market size remains to be validated
- •Watch for Phase 3 enrollment progress beginning H1 2027 and readout timeline (expected 2028-2029); also monitor whether Claris pursues IPO/SPAC before Phase 3 data and whether CSB-001 expands to additional indications
Claris BiotherapeuticsNovo HoldingsNovo NordiskCSB-001oremepermin alfa
→ Read original articleClinical Trials•Fierce Biotech•Jul 28, 2026
GSK partner Hansoh reports another phase 3 win for priority ADC
background ▾
- •Ris-rez met its primary endpoint in phase 3 relapsed osteosarcoma with significantly longer PFS versus chemotherapy, with consistent benefit in secondary endpoints including overall survival and no new safety signals
- •This is the second consecutive phase 3 win for ris-rez (following SCLC success), validating B7-H3 as a target and strengthening GSK's multi-indication ADC strategy ahead of planned genitourinary and other phase 3 trials
- •Watch for GSK's global Embold Sarcoma-202 trial readouts and planned phase 3 initiations in genitourinary cancers; also monitor Hansoh's China regulatory submission timeline and competitive positioning against Daiichi/Merck's I-DXd program
Hansoh PharmaceuticalGSKDaiichi Sankyorisvutatug rezetecanifinatamab deruxtecan
→ Read original articleClinical Trials•Fierce Biotech•Jul 28, 2026
Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win
background ▾
- •Pemvidutide achieved statistically significant superiority over placebo on the primary endpoint (4.2 vs. 2.75 fewer heavy drinking days/week) and showed robust biomarker validation with 38% reduction in serum phosphatidylethanol, a direct measure of alcohol consumption
- •The dual GLP-1/glucagon mechanism is positioned as potentially superior to GLP-1-only approaches in AUD due to glucagon's liver-directed effects, creating a differentiation argument against Novo's semaglutide and Lilly's GLP-1/GIP dual agonist brenipatide
- •Altimmune must secure additional funding to execute a pivotal AUD trial comparable in scale to Lilly's phase 3 programs (1,100 patients each), raising questions about timeline, competitive positioning, and capital requirements in a crowded GLP-1 AUD landscape
AltimmuneNovo NordiskEli Lillypemvidutidesemaglutidebrenipatide
→ Read original articleClinical Trials•Fierce Biotech•Jul 28, 2026
Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trial
background ▾
- •BEM/RZR achieved non-inferiority to Epclusa with 93.9% SVR and demonstrated equivalent efficacy in an 8-week treatment duration for non-cirrhotic patients, matching AbbVie's Mavyret treatment period advantage
- •The candidate met both FDA (modified intent-to-treat) and EMA (per-protocol) statistical analyses, positioning it favorably for global regulatory submissions across both regions
- •Watch for C-Forward phase 3 data (early 2026) in non-North American populations, which is critical for completing the regulatory dossier and assessing commercial potential in geographically diverse patient populations
Atea PharmaceuticalsGilead SciencesAbbViebemnifosbuvir/ruzasvirEpclusasofosbuvir/velpatasvir
→ Read original articleClinical Trials•Fierce Biotech•Jul 28, 2026
Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options
background ▾
- •INCB160058 terminated due to pharmacokinetic and bioavailability limitations that made continuation unjustifiable versus competing internal programs.
- •Incyte retains JAK2V617F focus through Prelude Therapeutics option agreement and plans to advance next-generation candidates with preclinical data disclosure anticipated later in 2024.
- •Monitor for preclinical data readout and advancement of Incyte's next-generation JAK2V617F program to assess whether pipeline transition yields more differentiated candidates.
IncytePrelude TherapeuticsAbbVieINCB160058JakafiZynyz
→ Read original article